The Cambridge Centre for Neuropsychiatric Research
The Bahn laboratory is conducting an extensive research program to define the molecular basis of major neuropsychiatric disorders. Our focus is on schizophrenia, bipolar affective disorder, major depressive disorder and autistic and anxiety spectrum disorders. The internationally recognized scientific team is supported by state of the art laboratory facilities at the Department of Chemical Engineering and Biotechnology, Cambridge. The Cambridge Centre for Neuropsychiatric Research (CCNR), under the direction of Prof Sabine Bahn conducts and coordinates fundamental and applied research into the causes and treatment of major neuropsychiatric disorders, focusing on biomarkers and novel target discovery with the mission to translate research findings from the bench to the patient bedside.
Following its foundation in 2004 the Bahn lab has received the second largest centre grant awarded by the Stanley Medical Research Institute (SMRI) and has continually attracted support and interest from prominent pharmaceutical companies and clinical partners around the world.
“CCNR starts and ends with patients”
- By using our combined medical expertise and novel CNS biomarker research and translational medicine technologies, we are gaining a better insight into CNS diseases pathophysiology, clinical phenoptype(s) and drug response.
- By introducing scientific rigour into prospective clinical protocols and bio-statistic analysis, we are able to translate derived complex multidimensional data into information that will help tp idntify disease biomarkers aiding patient stratification, drug efficacy and specific targets.
- To apply our knowledge of biomarkers, study design and system biology analyses to improve patients lifes.
- To build a large proteome database, generating potential novel in-silico candidate drug targets/biomarkers and companion diagnostics.
- To generate biologically validated ‘hard’ biomarkers for aiding diagnosis and drug efficacy “Theranostics” in CNS research.
- To significantly reduce drug attrition, and to contribute to R&D efforts in the pre/post competitive domain for the development of highly effective drugs through personalised medicine strategies.
- Applying state-of-the-art “omics” multiplex immunoassays, mass spectrometry (Label free LCMS and Selective Reaction Monitoring) and cytomics platforms to improve disease characterisation, definition of drug action and therapeutic response throughout all stages of CNS drug development.
- Optimizing study (Phase I-III clinical trials) designs to gain insight into disease aetiology and heterogeneity.
- Generating hypotheses, leading to novel therapeutic targets of significant biological effect.
- Providing predictive and surrogate tools in early development stages of pre-clinical and clinical models in collaboration with academic and pharmaceutical partners.